LYRA
Lyra Therapeutics, Inc.NASDAQHealthcare$0.44-11.98%ClosedMarket Cap: $781,126
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.64
P/S
1.96
EV/EBITDA
-0.49
DCF Value
$-2.81
FCF Yield
-3709.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-7794.5%
Net Margin
-7266.1%
ROE
1211.1%
ROA
-80.1%
ROIC
-98.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.0K | -1300.0% | $-7.5M | $-7.0M | $-9.60 | — |
| FY 2025 | $398.0K | 0.0% | $-31.0M | $-28.9M | $-18.62 | — |
| Q3 2025 | $25.0K | -300.0% | $-6.3M | $-6.0M | $-3.38 | — |
| Q2 2025 | $183.0K | -9.3% | $-8.4M | $-7.4M | $-5.51 | — |
| Q1 2025 | $183.0K | 100.0% | $-8.8M | $-8.5M | $-0.13 | — |
| Q4 2024 | $209.0K | 100.0% | $-11.4M | $-11.0M | $-0.17 | — |
| FY 2024 | $1.5M | 100.0% | $-96.3M | $-93.4M | $-1.43 | — |
| Q3 2024 | $195.0K | 100.0% | $-12.4M | $-11.9M | $-0.18 | — |
| Q2 2024 | $598.0K | 100.0% | $-49.0M | $-48.1M | $-0.73 | — |
| Q1 2024 | $532.0K | 74.4% | $-23.5M | $-22.5M | $-0.35 | — |
| Q4 2023 | $146.0K | 41.8% | $-16.5M | $-15.2M | $-0.25 | — |
| FY 2023 | $1.6M | 100.0% | $-67.1M | $-62.7M | $-1.26 | — |